601 related articles for article (PubMed ID: 16467118)
41. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
[TBL] [Abstract][Full Text] [Related]
42. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
43. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?
Burness ML; Grushko TA; Olopade OI
Cancer J; 2010; 16(1):23-32. PubMed ID: 20164687
[TBL] [Abstract][Full Text] [Related]
44. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
45. The role of sex steroid receptors in obstetrics and gynecology.
Roberts DK; Van Sickle M; Kelly RW
Obstet Gynecol Annu; 1983; 12():61-78. PubMed ID: 6866353
[TBL] [Abstract][Full Text] [Related]
46. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels.
Fitzpatrick SL; Brightwell J; Wittliff JL; Barrows GH; Schultz GS
Cancer Res; 1984 Aug; 44(8):3448-53. PubMed ID: 6331648
[TBL] [Abstract][Full Text] [Related]
47. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
48. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
49. Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas.
Di GH; Lu JS; Song CG; Li HC; Shen ZZ; Shao ZM
J Exp Clin Cancer Res; 2005 Dec; 24(4):601-7. PubMed ID: 16471323
[TBL] [Abstract][Full Text] [Related]
50. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
51. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
52. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
53. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
Mc Cormack O; Chung WY; Fitzpatrick P; Cooke F; Flynn B; Harrison M; Fox E; Gallagher E; McGoldrick A; Dervan PA; McCann A; Kerin MJ
Breast Cancer Res Treat; 2008 Sep; 111(1):45-53. PubMed ID: 17896177
[TBL] [Abstract][Full Text] [Related]
54. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
Skasko E; Paszko Z; Mazur S
Neoplasma; 2005; 52(1):10-7. PubMed ID: 15739020
[TBL] [Abstract][Full Text] [Related]
55. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells.
Hua KT; Way TD; Lin JK
Mol Carcinog; 2006 Aug; 45(8):551-60. PubMed ID: 16637063
[TBL] [Abstract][Full Text] [Related]
56. [Steroid receptors and breast carcinoma].
Pasić R; Dulbegović B; Softić D; Wittlif JL
Med Pregl; 1991; 44(1-2):48-51. PubMed ID: 1870463
[TBL] [Abstract][Full Text] [Related]
57. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
[TBL] [Abstract][Full Text] [Related]
58. [A study on the relationship between breast cancer molecular classification and prognosis].
Chen XS; Ma CD; Chen CM
Zhonghua Wai Ke Za Zhi; 2008 Sep; 46(18):1400-3. PubMed ID: 19094512
[TBL] [Abstract][Full Text] [Related]
59. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
[TBL] [Abstract][Full Text] [Related]
60. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
